Journal of Nephrology

, Volume 33, Issue 1, pp 101–107 | Cite as

Evaluation of inactive Matrix-Gla-Protein (MGP) as a biomarker for incident and recurrent kidney stones

  • Vincent CastiglioneEmail author
  • Hans Pottel
  • John Charles Lieske
  • Pierre Lukas
  • Etienne Cavalier
  • Pierre Delanaye
  • Andrew David Rule
Original Article



Matrix-Gla-protein (MGP) is an inhibitor of vascular calcification. Its dephosphorylated and uncarboxylated inactive form, dpucMGP, is a marker of vitamin K status and of cardio-vascular outcomes in chronic kidney disease. We hypothesized that higher serum dpucMGP would be a biomarker of kidney stone disease.


We measured serum dpucMGP in incident symptomatic kidney stone-formers and non-stone formers at a baseline visit. Symptomatic stone recurrence was assessed in the stones formers over a 5-year period. The association of dpucMGP with incident or recurrent kidney stones was assessed with and without adjustment for clinical, blood, and urine characteristics.


There was no significant difference in serum dpucMGP level between 498 stone formers and 395 non-stone former (510 vs 501 pmol/L; p = 0.66). In a multivariable model adjusting for clinical, blood and urine chemistries, higher MGP was associated with lower risk of stone formation (OR = 0.674, 95% CI 0.522–0.870), contrary to previous reports. Among 375 stone formers with 5 years of follow-up, 79 (21%) had symptomatic recurrence. No difference in serum dpucMGP was evident in recurrent versus non-recurrent stone-formers (482 vs 502 pmol/L; p = 0.26). Serum dpucMGP was correlated with cystatin C levels in non stone-formers, incident stone-formers and recurrent stone-formers (r > 0.3, p < 0.0001).


Elevated serum dpucMGP was not associated with incident or recurrent symptomatic kidney stone events. However, higher level of dpucMGP was associated with lower risk of kidney stone in a multivariable logistic regression model.


Nephrolithiais Matrix-Gla-protein Biomarker Cystatin C 



The authors would like to thanks IDS for providing the MGP reagents.

Compliance with ethical standards

Conflict of interest

PD and EC declare honoraria of consultancy for IDS. The results presented in this paper have not been published previously in whole or part, except in abstract format.

Ethical approval

This study is in accordance with the 1964 Declaration of Helsinki and has been approved by the Mayo Clinic Institutional Review Board (IRB:08–006541).

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Hale JE, Fraser JD, Price PA (1988) The identification of matrix Gla protein in cartilage. J Biol Chem 263:5820–5824PubMedGoogle Scholar
  2. 2.
    Evrard S, Delanaye P, Kamel S et al (2014) Vascular calcification: From pathophysiology to biomarkers. Clin Chim Acta 438:401–414. CrossRefPubMedGoogle Scholar
  3. 3.
    Schurgers LJ, Cranenburg ECM, Vermeer C (2008) Matrix Gla-protein: the calcification inhibitor in need of vitamin K. Thromb Haemost 100:593–603CrossRefGoogle Scholar
  4. 4.
    Delanaye P, Liabeuf S, Bouquegneau A et al (2015) The matrix-gla protein awakening may lead to the demise of vascular calcification. Nephrol Ther 11:191–200. CrossRefPubMedGoogle Scholar
  5. 5.
    Delanaye P, Krzesinski J-M, Warling X et al (2014) Dephosphorylated-uncarboxylated Matrix Gla protein concentration is predictive of vitamin K status and is correlated with vascular calcification in a cohort of hemodialysis patients. BMC Nephrol 15:145. CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Dalmeijer GW, Van der Schouw YT, Vermeer C et al (2013) Circulating matrix Gla protein is associated with coronary artery calcification and vitamin K status in healthy women. J Nutr Biochem 24:624–628. CrossRefPubMedGoogle Scholar
  7. 7.
    Liabeuf S, Olivier B, Vemeer C et al (2014) Vascular calcification in patients with type 2 diabetes: the involvement of matrix Gla protein. Cardiovasc Diabetol 13:85. CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Gao B, Yasui T, Lu X et al (2010) Matrix Gla protein expression in NRK-52E cells exposed to oxalate and calcium oxalate monohydrate crystals. Urol Int 85:237–241. CrossRefPubMedGoogle Scholar
  9. 9.
    Lu X, Gao B, Yasui T et al (2013) Matrix Gla protein is involved in crystal formation in kidney of hyperoxaluric rats. Kidney Blood Press Res 37:15–23. CrossRefPubMedGoogle Scholar
  10. 10.
    Lu X, Gao B, Liu Z et al (2012) A polymorphism of matrix Gla protein gene is associated with kidney stone in the Chinese Han population. Gene 511:127–130. CrossRefPubMedGoogle Scholar
  11. 11.
    Wei F-F, Thijs L, Zhang Z-Y, et al (2017) The risk of nephrolithiasis is causally related to inactive matrix Gla protein, a marker of vitamin K status: a Mendelian randomization study in a Flemish population. Nephrol Dial Transpl. CrossRefGoogle Scholar
  12. 12.
    Haley WE, Enders FT, Vaughan LE et al (2016) Kidney function after the first kidney stone event. Mayo Clin Proc 91:1744–1752. CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Khan A, Wang W, Khan SR (2014) Calcium oxalate nephrolithiasis and expression of matrix GLA protein in the kidneys. World J Urol 32:123–130. CrossRefPubMedGoogle Scholar
  14. 14.
    Khan SR, Joshi S, Wang W, Peck AB (2014) Regulation of macromolecular modulators of urinary stone formation by reactive oxygen species: transcriptional study in an animal model of hyperoxaluria. Am J Physiol Renal Physiol 306:F1285–F1295. CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Joshi S, Clapp WL, Wang W, Khan SR (2015) Osteogenic changes in kidneys of hyperoxaluric rats. Biochim Biophys Acta Mol Basis Dis 1852:2000–2012. CrossRefGoogle Scholar
  16. 16.
    Yasui T, Fujita K, Sasaki S, et al (1999) Expression of bone matrix proteins in urolithiasis model rats. Urol Res 27:255–261CrossRefGoogle Scholar
  17. 17.
    Wang Q, Hu H, Dirie NI et al (2018) High concentration of calcium promotes mineralization in NRK52E cells via inhibiting the expression of matrix Gla protein. Urology. CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Dalmeijer GW, van der Schouw YT, Magdeleyns E et al (2012) The effect of menaquinone-7 supplementation on circulating species of matrix Gla protein. Atherosclerosis 225:397–402. CrossRefPubMedGoogle Scholar
  19. 19.
    Goiko M, Dierolf J, Gleberzon JS et al (2013) Peptides of Matrix Gla protein inhibit nucleation and growth of hydroxyapatite and calcium oxalate monohydrate crystals. PLoS One 8:e80344. CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Singh P, Enders FT, Vaughan LE et al (2015) Stone composition among first-time symptomatic kidney stone formers in the community. Mayo Clin Proc 90:1356–1365. CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Murugesan A, Kumar L, Janarthanan P (2018) Status of single nucleotide polymorphism of matrix gla protein gene (rs4236) in Nephrolithiasis: a preliminary study in indian population. Int J Appl Basic Med Res 8:38. CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Gao B, Yasui T, Itoh Y et al (2007) A polymorphism of matrix Gla protein gene is associated with kidney stones. J Urol 177:2361–2365. CrossRefPubMedGoogle Scholar
  23. 23.
    Zhu M, Zeng F, Cui Y, et al (2017) Expression of matrix Gla protein and bone morphogenetic protein 2 in renal papillary tissues in patients with calcium oxalate kidney stones. J Cent South Univ Med Sci 42:277–283. CrossRefGoogle Scholar
  24. 24.
    Puzantian H, Akers SR, Oldland G et al (2018) Circulating dephospho-uncarboxylated matrix gla-protein is associated with kidney dysfunction and arterial stiffness. Am J Hypertens 31:988–994. CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Kurnatowska I, Grzelak P, Masajtis-Zagajewska A et al (2016) Plasma desphospho-uncarboxylated matrix gla protein as a marker of kidney damage and cardiovascular risk in advanced stage of chronic kidney disease. Kidney Blood Press Res 41:231–239. CrossRefPubMedGoogle Scholar
  26. 26.
    Sorensen MD, Hsi RS, Chi T et al (2014) Dietary intake of fiber, fruit and vegetables decreases the risk of incident kidney stones in women: a women’s health initiative report. J Urol 192:1694–1699. CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Italian Society of Nephrology 2019

Authors and Affiliations

  1. 1.Department of Clinical ChemistryCHU of Liège, University of Liège (ULg CHU)LiègeBelgium
  2. 2.Department of Public Health and Primary CareKU Leuven Campus Kulak KortrijkKortrijkBelgium
  3. 3.Division of Nephrology and HypertensionMayo ClinicRochesterUSA
  4. 4.Department of Nephrology, Dialysis and TransplantationCHU of Liège, University of Liège (ULg CHU)LiègeBelgium

Personalised recommendations